Greenwood Capital Associates LLC Buys 2,673 Shares of Eli Lilly and Company $LLY

Greenwood Capital Associates LLC grew its position in shares of Eli Lilly and Company (NYSE:LLY) by 25.5% during the third quarter, HoldingsChannel reports. The institutional investor owned 13,169 shares of the company’s stock after purchasing an additional 2,673 shares during the period. Eli Lilly and Company comprises 1.2% of Greenwood Capital Associates LLC’s investment portfolio, making the stock its 18th largest position. Greenwood Capital Associates LLC’s holdings in Eli Lilly and Company were worth $10,048,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of LLY. Laurel Wealth Advisors LLC boosted its stake in shares of Eli Lilly and Company by 78,621.2% in the 2nd quarter. Laurel Wealth Advisors LLC now owns 11,552,336 shares of the company’s stock worth $9,005,392,000 after buying an additional 11,537,661 shares during the last quarter. Norges Bank purchased a new stake in Eli Lilly and Company in the 2nd quarter worth approximately $8,827,714,000. Vanguard Group Inc. raised its position in shares of Eli Lilly and Company by 1.5% during the 2nd quarter. Vanguard Group Inc. now owns 80,407,430 shares of the company’s stock valued at $62,680,004,000 after purchasing an additional 1,183,038 shares during the period. Assenagon Asset Management S.A. lifted its position in shares of Eli Lilly and Company by 106.8% in the second quarter. Assenagon Asset Management S.A. now owns 1,481,031 shares of the company’s stock valued at $1,154,508,000 after acquiring an additional 765,010 shares in the last quarter. Finally, Franklin Resources Inc. boosted its stake in Eli Lilly and Company by 13.4% in the 2nd quarter. Franklin Resources Inc. now owns 4,766,865 shares of the company’s stock worth $3,715,913,000 after purchasing an additional 564,736 shares during the period. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Price Performance

Shares of LLY opened at $1,077.26 on Monday. The business’s 50-day moving average is $986.75 and its two-hundred day moving average is $841.60. The company has a debt-to-equity ratio of 1.71, a quick ratio of 1.24 and a current ratio of 1.55. The company has a market capitalization of $1.02 trillion, a P/E ratio of 52.70, a P/E/G ratio of 1.09 and a beta of 0.37. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,111.99.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The business had revenue of $17.60 billion for the quarter, compared to analyst estimates of $16.09 billion. During the same period in the prior year, the company posted $1.18 EPS. The company’s revenue for the quarter was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Research analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be issued a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 0.6%. The ex-dividend date is Friday, February 13th. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 29.35%.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on LLY shares. Daiwa America upgraded Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a report on Tuesday, December 16th. Sanford C. Bernstein reiterated an “outperform” rating on shares of Eli Lilly and Company in a report on Friday, December 19th. BMO Capital Markets set a $1,200.00 price objective on shares of Eli Lilly and Company in a report on Thursday, December 4th. JPMorgan Chase & Co. upped their target price on Eli Lilly and Company from $1,050.00 to $1,150.00 and gave the stock an “overweight” rating in a report on Tuesday, November 18th. Finally, UBS Group reiterated a “neutral” rating on shares of Eli Lilly and Company in a research note on Thursday, December 18th. Four analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and five have given a Hold rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $1,155.36.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.